Abstracts

Risk of Cancer in Children Exposed to Didanosine in Utero

Antiretroviral treatment during pregnancy has been effective in reducing perinatal HIV transmission. Some nucleos(t)ide reverse transcriptase inhibitors (NRTIs) display genotoxicity in vitro so we evaluated the incidence of cancer among children exposed to NRTIs in utero between 1990 and 2014 in the ANRS French Perinatal Cohort (EPF). We updated the evaluation of cancer incidence among…

ARV Risk for Speech and Language Impairments in HEU Children at 3 and 5 Years

Perinatally HIV-exposed but uninfected (PHEU) children have elevated risk of late language emergence at age 1 year, with possible links to in utero antiretroviral (ARV) exposure. This study investigated possible risks, including ARV exposure, for speech impairments (SI) and language impairments (LI) in monolingual PHEU children in the important preschool period. This is the first…

Longitudinal Evaluation of Language Impairment in Perinatally HIV Exposed Adolescents

We previously documented  a significantly higher prevalence (relative to comparable communities) of both primary language impairment (PLI) and language impairment concomitant with hearing/cognitive impairments (CLI) in perinatally HIV-infected (PHIV) and perinatally HIV-exposed uninfected (PHEU) participants (age range: 7-17y) from the Adolescent Master Protocol (AMP), a component of PHACS. This analysis describes longitudinal outcomes of this…

48-Week Outcomes of African Children Starting ART at CD4>500 With Streamlined Care

With global guidelines shifting to universal antiretroviral therapy (ART) for HIV+ children, strategies are needed to scale-up ART efficiently while ensuring good clinical outcomes.  Data on children initiating ART at high CD4 counts are particularly limited. We evaluated retention in care, viral suppression, and safety in asymptomatic HIV+ children starting ART at CD4> 500 cells/μl…

Family Clinic Day RCT in Uganda: Child Antiretroviral Therapy Retention and Adherence

Uganda recently adopted a test-and-treat policy for HIV patients 15 years or younger. But despite increased eligibility, low retention rates among pediatric and adolescent antiretroviral therapy (ART) initiates could severely limit the impact of this new policy. This evaluation tested the impact of the Family Clinic Day (FCD) program, a facility based family-centered appointment scheduling…